Atara Biotherapeutics Inc Logo
US0465132068

Atara Biotherapeutics Inc

Ins Portfolio
Kostengünstig und breit gestreut in Europa investieren. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +8,81(+29,37%). Der Median liegt bei +8,53(+25,26%).

Kaufen
  4
Halten
  6
Verkaufen
  2

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The o.» Mehr auf businesswire.com


  • Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates. “We are pleased that we have secured additional financing that is expected to extend our cash runway through the first quarter of 2026,” sai.» Mehr auf businesswire.com


  • Atara Biotherapeutics Announces Pricing of $16 Million Offering

    THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6.» Mehr auf businesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Atara Biotherapeutics Inc einen Umsatz von +90,72 Mio und ein Nettoeinkommen von +35,13 Mio
(EUR)März 2025
YOY
Umsatz+90,72 Mio257,91%
Bruttoeinkommen+71,83 Mio205,55%
Nettoeinkommen+35,13 Mio111,94%
EBITDA+37,73 Mio239,54%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+46,16 Mio
Anzahl Aktien
6,80 Mio
52 Wochen-Hoch/Tief
+15,96 - +4,27
DividendenNein
Beta
0,18
KGV (PE Ratio)
5,48
KGWV (PEG Ratio)
0,08
KBV (PB Ratio)
1,56
KUV (PS Ratio)
+0,53

Unternehmensprofil

Name
Atara Biotherapeutics Inc
CEO
Anhco Nguyen
Mitarbeiter153

Assets entdecken

Shareholder von Atara Biotherapeutics Inc investieren auch in folgende Assets

🍪

Parqet nutzt Cookies.Erfahre Mehr